JG
TVTX icon

Jain Global’s Travere Therapeutics TVTX Stock Holding History

Jain Global’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,117
Closed -$768K – 1529
2025
Q3 		$768K Buy
+32,117
New +$604K ﹤0.01% 681
2025
Q2 		– Sell
-101,695
Closed -$1.82M – 1621
2025
Q1 		$1.82M Buy
+101,695
New +$2.06M 0.02% 369

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jain Global's TVTX Position: Q4 2025 in Review

Jain Global sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 32,117 shares — an estimated $768K sold.

Jain Global first reported a position in TVTX in Q1 2025 and held it in 2 quarters. The position peaked at $1.82M in Q1 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Jain Global reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jain Global sold 32,117 Travere Therapeutics shares in Q4 2025, an estimated $768K.
  • Jain Global first reported a position in Travere Therapeutics in Q1 2025 and held it in 2 quarters.
  • Jain Global's Travere Therapeutics position peaked at $1.82M in Q1 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Jain Global's 13F filing for Q4 2025, filed 17 Feb 2026.